Objective: Statins are extensively used for lowering LDL-cholesterol and reducing cardiovascular events. Recent studies have shown that statins have beneficial anti-inflammatory effects. We aimed to determine whether and how adipokines are regulated during statin treatment in type 2 diabetic patients.
Method: In this study,we investigated the changes of CRP and inflammation-related adipokines (SAA,IL-6,TNFα and adiponectin) in 23 type 2 diabetic patients with atherosclerosis who received statin therapy, and 20 diabetic patients with atherosclerosis and 14 diabetic patients without atherosclerosis who did not receive statin therapy for a period of three months.
Results: By the end of the simvastatin treatment (40 mg, daily), LDL-cholesterol was decreased by 16.7% and HDL-cholesterol was increased by 31.9%. SAA, CRP, TNFα and IL-6 levels were decreased by 31.8%, 66.2%, 53.9% and 14%, respectively and adiponectin was increased by 59.6%, compared with the baseline levels. Interestingly, the decrease of SAA was positively correlated with that of LDL-cholesterol but negatively with HDL-cholesterol during statin treatment. Among the adipokines, the decrease of SAA was positively correlated with TNFα (r = 0.50, p = 0.016).
Conclusion: The results suggest that adipokines may be differentially regulated and independent of cholesterol changes and that adipokines may be a mediator, and the adipose tissue may be a target of statins’ anti-inflammatory effect.
Tracy RP ( 2003) Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl134: 10-7.
2.
Koenig W., Sund M., Frohlich M., et al. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation99: 237-42.
3.
Ridker PM, Stampfer MJ, Rifai N. ( 2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease . JAMA285: 2481-5.
4.
Leinonen E., Hurt-Camejo E., Wiklund O., Hulten LM, Hiukka A., Taskinen MR ( 2003) Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes . Atherosclerosis166: 387-94.
5.
Ridker PM, Danielson E., Fonseca FA, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med359: 2195-207.
6.
Sidhu JS, Kaposzta Z., Markus HS, Kaski JC ( 2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol24: 930-4.
7.
Langenfeld MR , Forst T., Hohber C., et al. (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study . Circulation111: 2525-31.
8.
Jialal I., Stein D., Balis D., Grundy SM, Adams-Huet B., Devaraj S. ( 2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation103: 1933-5.
9.
Devaraj S., Chan E., Jialal I. ( 2006) Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab91: 4489-96.
10.
Kinlay S., Schwartz GG, Olsson AG, et al. (2003) High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation108: 1560-6.
11.
Lefer DJ ( 2002) Statins as potent antiinflammatory drugs. Circulation106: 2041-2.
12.
Albert MA, Danielson E., Rifai N., Ridker PM ( 2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA286: 64-70.
13.
Chan KY, Boucher ES, Gandhi PJ, Silva MA ( 2004) HMGCoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm61: 1676-81.
14.
Hognestad A. , Aukrust P., Wergeland R., et al. (2004) Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation . Clin Cardiol27: 199-203.
15.
Holm T., Andreassen AK, Ueland T., et al. (2001) Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol87: 815-8, A9.
16.
Bouloumie A. , Casteilla L., Lafontan M. (2008) Adipose tissue lymphocytes and macrophages in obesity and insulin resistance: makers or markers, and which comes first?Arterioscler Thromb Vasc Biol28: 1211-3.
17.
Hotamisligil GS, Arner P., Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance . J Clin Invest95: 2409-15.
18.
Fried SK, Bunkin DA, Greenberg AS ( 1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid . J Clin Endocrinol Metab83: 847-50.
19.
Shimomura I. , Funahashi T., Takahashi M., et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity . Nat Med2: 800-3.
20.
Lehrke M., Lazar MA ( 2004) Inflamed about obesity. Nat Med10: 126-7.
21.
Poitou C., Viguerie N., Cancello R., et al. (2005) Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia48: 519-28.
22.
Yang RZ, Lee MJ, Hu H., et al. (2006) Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications . PLoS Med3: e287.
23.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. (1997) Diabetes Care20: 1183-97.
24.
Fox CS, Coady S., Sorlie PD, et al. (2004) Trends in cardiovascular complications of diabetes. JAMA292: 2495-9.
25.
Cubbon R., Kahn M., Kearney MT ( 2008) Secondary prevention of cardiovascular disease in type 2 diabetes and pre-diabetes: a cardiologist’s perspective. Int J Clin Pract62: 287-99.
26.
Haffner SM ( 2004) Dyslipidemia management in adults with diabetes . Diabetes Care27(suppl 1):S68-S71.
27.
Ali YS, Linton MF, Fazio S. ( 2008) Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr Opin Endocrinol Diabetes Obes15: 142-6.
28.
Rugina M., Caras I., Jurcut R., et al. (2007) Systemic inflammatory markers in patients with aortic sclerosis. Roum Arch Microbiol Immunol66: 10-6.
29.
Magyar MT, Szikszai Z., Balla J., et al. (2003) Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke34: 58-63.
30.
Benditt EP, Hoffman JS, Eriksen N., Parmelee DC, Walsh KA ( 1982) SAA, an apoprotein of HDL: its structure and function . Ann N Y Acad Sci389: 183-9.
31.
Wu A., Hinds CJ, Thiemermann C. ( 2004) High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock21: 210-21.
32.
Furlaneto CJ , Campa A. (2000) A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun268: 405-8.
33.
Thorn CF, Lu ZY, Whitehead AS ( 2004) Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol59: 152-8.
34.
Walter DH, Fichtlscherer S., Britten MB, et al. (2001) Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol38: 2006-12.
35.
Bickel C., Rupprecht HJ, Blankenberg S., et al. (2002) Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol89: 901-8.
36.
Okura H., Asawa K., Kubo T., et al. (2007) Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure . Intern Med46: 1337-43.
37.
Ky B., Rader DJ ( 2005) The effects of statin therapy on plasma markers of inflammation in patients without vascular disease. Clin Cardiol28: 67-70.
38.
Johnson BD, Kip KE, Marroquin OC, et al. (2004) Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) . Circulation109: 726-32.
